- Home
- CRVS
as 04-02-2025 4:00pm EST
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BURLINGAME |
| Market Cap: | 257.0M | IPO Year: | 2016 |
| Target Price: | $12.63 | AVG Volume (30 days): | 704.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.30 - $10.00 | Next Earning Date: | 05-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Corvus Pharmaceuticals Inc. News
CRVS Breaking Stock News: Dive into CRVS Ticker-Specific Updates for Smart Investing
Thomson Reuters StreetEvents
7 days ago
Q4 2024 Corvus Pharmaceuticals Inc Earnings Call
Simply Wall St.
8 days ago
Insider Buyers At Corvus Pharmaceuticals Sitting On US$1.3m Profit
MT Newswires
8 days ago
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $15 From $14, Maintains Outperform Rating
GuruFocus.com
8 days ago
Corvus Pharmaceuticals Inc (CRVS) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...
Associated Press Finance
8 days ago
Corvus: Q4 Earnings Snapshot
GlobeNewswire
8 days ago
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
14 days ago
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma
GlobeNewswire
14 days ago
Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Compare CRVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRVS Corvus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.